Evolut TAVI (system of implantation of the aortal valve)

2020: The announcement of the device for implantation of the aortal Evolut TAVI valve

At the end of June, 2020 Medtronic released the new system of transkateterny implantation of the aortal valve. The solution Evolut TAVI which already went on sale in the European market it is shown to patients with the heavy stenosis of an aorta having low risk of a lethal outcome when carrying out transaction. The indications approved in Europe cover all risk categories at patients with a heavy aortal stenosis.

Results of global randomized study in which three generations of the new implanted valves in comparison with surgical prosthetics of valves at more than 1400 patients were estimated showed that the system of transkateterny implantation of the aortal valve is an effective method of treatment of patients with low risk and improves 30-day figures of merit of life in comparison with traditional techniques.

Medtronic released the new system of transkateterny implantation of the aortal valve

Besides, as the producer claims, the Evolut installation provided high rates of haemo dynamics with lower average pressure gradient about the aortal valve. At the same time the area of an aortal opening within one year was higher, than at traditional surgical intervention.

The Evolut system includes the self-extending framework from a nitinol who allows the implanted valve to nestle on a fibrous ring with a permanent force and also outer fabric jacket which increases the area of contact with natural anatomical structures and by that provides sealing of the valve.

Now more and more patients will be able to receive treatment using the Evolut system while the area of surgical prosthetics of the aortal valve will continue to develop to help patients with even more difficult statuses — the vice president of Medtronic and the chief physician of division of structural surgery of heart doctor Pieter Kappetein noted.[1]

Notes